Sotera Health (SHC) Scheduled to Post Quarterly Earnings on Thursday

Sotera Health (NASDAQ:SHC) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.12 per share for the quarter. Sotera Health has set its FY24 guidance at $0.67 to $0.75 EPS and its FY 2024 guidance at 0.670-0.750 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Sotera Health had a net margin of 4.90% and a return on equity of 51.32%. The company had revenue of $310.24 million during the quarter, compared to the consensus estimate of $302.17 million. During the same period in the prior year, the business posted $0.23 EPS. The company’s quarterly revenue was up 23.3% on a year-over-year basis. On average, analysts expect Sotera Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sotera Health Trading Down 1.0 %

Sotera Health stock opened at $11.27 on Thursday. The firm has a 50-day moving average of $13.20 and a 200-day moving average of $14.13. Sotera Health has a one year low of $10.71 and a one year high of $19.40. The company has a debt-to-equity ratio of 5.16, a current ratio of 2.42 and a quick ratio of 2.21. The company has a market cap of $3.19 billion, a price-to-earnings ratio of 62.61 and a beta of 2.11.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SHC shares. TheStreet upgraded shares of Sotera Health from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. Barclays cut their target price on shares of Sotera Health from $19.00 to $14.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. KeyCorp assumed coverage on shares of Sotera Health in a report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Jefferies Financial Group raised shares of Sotera Health from a “hold” rating to a “buy” rating and increased their price target for the company from $15.00 to $15.50 in a report on Monday, March 25th. Finally, Citigroup raised shares of Sotera Health from a “neutral” rating to a “buy” rating and lowered their price target for the company from $18.00 to $16.00 in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.70.

Insider Activity at Sotera Health

In related news, Director Pincus & Co. Warburg sold 16,594,363 shares of Sotera Health stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.31, for a total value of $237,465,334.53. Following the transaction, the director now directly owns 88,822,952 shares of the company’s stock, valued at $1,271,056,443.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Sotera Health news, insider Michael P. Rutz sold 83,109 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.31, for a total value of $1,189,289.79. Following the sale, the insider now owns 544,409 shares in the company, valued at $7,790,492.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pincus & Co. Warburg sold 16,594,363 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the completion of the sale, the director now owns 88,822,952 shares in the company, valued at approximately $1,271,056,443.12. The disclosure for this sale can be found here. 55.12% of the stock is currently owned by insiders.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.